The Japan clinical trials market was valued at USD 1.61 Billion in 2025 and is expected to grow at a CAGR of 5.70%, reaching USD 2.80 Billion by 2035. The market growth is driven by rising demand for innovative therapies and stringent regulatory compliance.
Base Year
Historical Period
Forecast Period
The growing focus on integrating AI, digital technologies, and patient-centric approaches to streamline trial processes is expected to impact the market dynamics in the forecast period.
The rising regulatory reforms in Japan, designed to speed up drug approvals and reduce the drug lag, are projected to elevate the Japan clinical trials market value in the coming years.
The increasing private equity interest in Japan's healthcare sector is set to support market expansion.
Compound Annual Growth Rate
5.7%
Value in USD Billion
2026-2035
*this image is indicative*
Japan is considered one of the largest clinical trial markets in Asia, driven by its advanced healthcare infrastructure, aging population, and strong government support for medical innovation. Recent market trends show increasing adoption of decentralized clinical trial models, with greater use of digital health tools to reach a broader patient base. With rising demand for personalized medicine and innovative therapies, the clinical trial market in Japan is expected to witness a positive growth trajectory in the coming years.
Increasing Clinical Trial Activity to Drive Market Growth
In Japan, a study has shown that over 90% of adults aged 75 or older suffer from at least one chronic disease, with approximately 80% of them managing multiple conditions. This highlights the need to optimize healthcare strategies to better support individuals living with chronic diseases. The growing burden of these conditions is also driving an increased demand for clinical trials in Japan, which is projected to bolster the market growth.
The market is witnessing several trends and developments to improve the current scenario, including growing AI integration and rising strategic partnerships enhancing clinical trial efficiency and demand.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Phase
Market Breakup by Service Type
Market Breakup by Therapeutic Areas
Market Breakup by Application
The Phase III Segment Holds a Substantial Market Share
Based on the phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV clinical trials. Phase III holds a substantial market share in Japan, driven by the rising number of late-stage drug development programs, increasing demand for large-scale efficacy trials, and growing focus on therapeutic validation before regulatory approval. The complexity, duration, and costs associated with Phase III trials also contribute significantly to overall market revenue.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
IQVIA is a major player in the Japan clinical trials market, leveraging its IQVIA CORE™ platform to enhance study design, patient recruitment, and data-driven trial optimization. With a strong local presence, the company supports trials across all phases and works closely with Japanese regulatory bodies to streamline approvals and execution.
Caidya significantly contributes to the Japan clinical trials market growth with its robust operational footprint and in-depth understanding of the regional regulatory environment. The company offers full-service CRO solutions tailored for Japan, helping global sponsors accelerate study timelines through digital tools and experienced site networks.
Parexel is one of the leading market players and is actively involved in Japan’s clinical trials sector. The company’s operations in Japan focus on optimizing trial delivery through partnerships with local investigators and leveraging digital solutions to improve patient recruitment and retention in compliance with Japan’s stringent trial requirements.
Syneos Health strengthens Japan’s clinical trials landscape through its tailored development and commercialization services. The company focuses on combining local regulatory expertise with global trial execution capabilities. Its decentralized trial solutions and digital engagement strategies are particularly aligned with the growing emphasis on patient-centric research models.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include SGS AG, Wuxi AppTec Co Ltd, ICON plc, and Novo Nordisk A/S ADR.
Upto 15% Off
USD
$3099 $2789
$1999 $1799
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Phase |
|
| Breakup by Service Type |
|
| Breakup by Therapeutic Areas |
|
| Breakup by Application |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share